TY - JOUR
T1 - Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation
AU - Afrough, Aimaz
AU - Pasvolsky, Oren
AU - Ma, Junsheng
AU - Srour, Samer
AU - Bashir, Qaiser
AU - Saini, Neeraj
AU - Hosing, Chitra
AU - Popat, Uday R.
AU - Kebriaei, Partow
AU - Delgado, Ruby
AU - Ullah, Muhammad R.
AU - Murphy, Regan
AU - Manasanch, Elisabet E.
AU - Lee, Hans C.
AU - Kaufman, Gregory P.
AU - Patel, Krina K.
AU - Thomas, Sheeba K.
AU - Weber, Donna M.
AU - Orlowski, Robert Z.
AU - Shpall, Elizabeth J.
AU - Champlin, Richard E.
AU - Qazilbash, Muzaffar H.
N1 - Funding Information:
Financial disclosure: None to report. Conflict of interest statement: M.H.Q has grant or research support through Janssen, Angiocrine, and Amgen, and consultancy with Bioclinica. Q.B. has research support through Takeda Pharmaceuticals, Stemline Therapeutics, and Acrotech Biopharma and serves on advisory boards for Purdue Pharma, Spectrum Pharmaceuticals, Kite Pharma, Takeda Pharmaceuticals, and Amgen. E.M. has research support through Sanofi, Quest Diagnostics, Novartis, JW Pharma, and Merck and consultancy with GSK, Secura Bio, Takeda Pharmaceuticals, Celgene, Sanofi, Janssen, and Adaptive Biotechnologies. H.C.L. has research support through Takeda Pharmaceuticals, Amgen, Celgene, Janssen, and Regeneron and consultancy with Bristol-Myers Squibb, Celgene, Genentech, GlaxoSmithKline, Immunitis Therapeutics, Janssen, Karyopharm Therapeutics, Legend Biotech, Oncopeptides, Sanfo-Aventis, and Takeda Pharmaceuticals. G.P.K. has research support through BMS and Janssen. Authorship statement: M.H.Q and A.A contributed to the design and implementation of the research; J.M. analyzed and interpreted the data; S.S, Q.B. N.S, C.H. U.R.P. P.K. R.M. E.E.M. H.C.L. G.P.K. K.K.P. S.K.T. D.M.W, R.Z.O. E.J.S. R.E.C. M.H.Q. cared for all patients; A.A. O.P. and R.D. collected and assembled the data; A.A. and M.H.Q. wrote the manuscript; and all authors approved the final draft of the manuscript and are accountable for all aspects of the work. Financial disclosure: See Acknowledgments on page 307.e12.
Publisher Copyright:
© 2022 The American Society for Transplantation and Cellular Therapy
PY - 2022/6
Y1 - 2022/6
N2 - Induction therapy with a triplet regimen, followed by high-dose therapy and autologous hematopoietic stem cell transplantation (auto-HCT), is the standard of care for newly diagnosed, transplant-eligible patients with multiple myeloma (MM). Bortezomib-dexamethasone with cyclophosphamide (VCD) or lenalidomide (VRD) are the most used induction regimens. However, previous studies comparing VCD and VRD showed disparate results. The goal of this retrospective study was to compare the “real-world” results of VCD and VRD in transplant-eligible MM patients outside of a clinical trial. We identified 322 patients who received VRD or VCD induction before auto-HCT at our institution. All patients received melphalan conditioning and single-agent lenalidomide maintenance therapy. Overall, 114 patients received VCD, and 208 received VRD. The median age at auto-HCT was 61.9 years (range 33.9-79.6), with 35.4% (114/322) of the cohort being 65 years of age or older. The overall response rate was 99.7% after auto-HCT, with a significantly lower complete remission rate as the final response in the VCD compared to the VRD group (34% versus 53%; P = .001). However, there was no significant difference between the best response rate of very good partial response (VGPR) or better in the VCD compared to the VRD group (92% versus 85%; P = .078). The median duration of ≥VGPR was 50.0 months (95% confidence interval [CI], 42.0-69.1) for both cohorts, and there was no difference between VCD and VRD (P = .769; hazard ratio, 0.95; 95% CI, 0.69-1.31). Median follow-up of survivors was 73 months. There was no difference in the relapse rate between VCD and VRD (P = .749). Median progression-free survival (PFS) was 48.7 months in the VCD and 44.6 months in the VRD group (P = .858). Median overall survival (OS) was 103.8 months with VCD and 101.7 months with VRD (P = .891). At 5 years, the PFS and OS were 38.1% and 76.9% for the VCD group, respectively, and 40.7% and 74.6% for the VRD group, respectively. On multivariate analysis for OS in the entire cohort, Revised International Staging System I and post-auto-HCT best response of stringent complete response (sCR)/CR emerged as significant predictors of superior OS. There was no impact of the type of induction regimen on the OS in the multivariate analysis. Induction therapy with VCD compared to VRD was associated with a lower CR rate, but there was no difference in PFS or OS between the 2 regimens.
AB - Induction therapy with a triplet regimen, followed by high-dose therapy and autologous hematopoietic stem cell transplantation (auto-HCT), is the standard of care for newly diagnosed, transplant-eligible patients with multiple myeloma (MM). Bortezomib-dexamethasone with cyclophosphamide (VCD) or lenalidomide (VRD) are the most used induction regimens. However, previous studies comparing VCD and VRD showed disparate results. The goal of this retrospective study was to compare the “real-world” results of VCD and VRD in transplant-eligible MM patients outside of a clinical trial. We identified 322 patients who received VRD or VCD induction before auto-HCT at our institution. All patients received melphalan conditioning and single-agent lenalidomide maintenance therapy. Overall, 114 patients received VCD, and 208 received VRD. The median age at auto-HCT was 61.9 years (range 33.9-79.6), with 35.4% (114/322) of the cohort being 65 years of age or older. The overall response rate was 99.7% after auto-HCT, with a significantly lower complete remission rate as the final response in the VCD compared to the VRD group (34% versus 53%; P = .001). However, there was no significant difference between the best response rate of very good partial response (VGPR) or better in the VCD compared to the VRD group (92% versus 85%; P = .078). The median duration of ≥VGPR was 50.0 months (95% confidence interval [CI], 42.0-69.1) for both cohorts, and there was no difference between VCD and VRD (P = .769; hazard ratio, 0.95; 95% CI, 0.69-1.31). Median follow-up of survivors was 73 months. There was no difference in the relapse rate between VCD and VRD (P = .749). Median progression-free survival (PFS) was 48.7 months in the VCD and 44.6 months in the VRD group (P = .858). Median overall survival (OS) was 103.8 months with VCD and 101.7 months with VRD (P = .891). At 5 years, the PFS and OS were 38.1% and 76.9% for the VCD group, respectively, and 40.7% and 74.6% for the VRD group, respectively. On multivariate analysis for OS in the entire cohort, Revised International Staging System I and post-auto-HCT best response of stringent complete response (sCR)/CR emerged as significant predictors of superior OS. There was no impact of the type of induction regimen on the OS in the multivariate analysis. Induction therapy with VCD compared to VRD was associated with a lower CR rate, but there was no difference in PFS or OS between the 2 regimens.
KW - Autologous hematopoietic stem cell transplantation
KW - Induction therapy
KW - Multiple myeloma
KW - VCD
KW - VRD
UR - http://www.scopus.com/inward/record.url?scp=85131639396&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131639396&partnerID=8YFLogxK
U2 - 10.1016/j.jtct.2022.03.020
DO - 10.1016/j.jtct.2022.03.020
M3 - Article
C2 - 35331973
AN - SCOPUS:85131639396
SN - 2666-6375
VL - 28
SP - 307.e1-307.e8
JO - Transplantation and Cellular Therapy
JF - Transplantation and Cellular Therapy
IS - 6
ER -